Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Androgen Receptor Variant 7 (AR-V7) Transcript Expression in Circulating Tumor Cells.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Androgen Receptor Variant 7 (AR-V7) Protein Detection in Circulating Tumor Cells by Immunocytostaining.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Pyrrolic-N-directed Fe single-atom seeding tunes O<sub>2</sub> dipole moments for boosted oxygen reduction.

Science bulletin·2026
Same author

The innate immune mediator group IIA secreted phospholipase A<sub>2</sub> modulates lipid droplet formation in prostate cancer cells.

Frontiers in cell and developmental biology·2026
Same author

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use.

Journal for immunotherapy of cancer·2026
Same author

From Spatial Heterogeneity to Real-Time Monitoring: Liquid Biopsy for Genomic Profiling and MRD Assessment in Multiple Myeloma.

Cancers·2026

Related Experiment Video

Updated: Nov 14, 2025

Detection and Isolation of Circulating Melanoma Cells using Photoacoustic Flowmetry
09:52

Detection and Isolation of Circulating Melanoma Cells using Photoacoustic Flowmetry

Published on: November 25, 2011

16.1K

PD-L1 Detection on Circulating Melanoma Cells.

Joseph W Po1,2,3, Yafeng Ma4,5,6, Bavanthi Balakrishnar7

  • 1Centre for Circulating Tumour Cell Diagnostics & Research at the Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia. joseph.po@health.nsw.gov.au.

Methods in Molecular Biology (Clifton, N.J.)
|March 11, 2021
PubMed
Summary

Researchers developed a new method to analyze PD-L1 expression on circulating melanoma cells. This could help predict patient response to immune checkpoint inhibitors (ICIs) and improve melanoma treatment.

Keywords:
Circulating tumor cells (CTC)ImmunotherapyLiquid biopsyMelanomaPD-L1

More Related Videos

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.6K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K

Related Experiment Videos

Last Updated: Nov 14, 2025

Detection and Isolation of Circulating Melanoma Cells using Photoacoustic Flowmetry
09:52

Detection and Isolation of Circulating Melanoma Cells using Photoacoustic Flowmetry

Published on: November 25, 2011

16.1K
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.6K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Personalized medicines targeting cell signaling pathways have improved melanoma outcomes.
  • Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are effective but only in a subset of melanoma patients.
  • ICIs are associated with significant toxicities, necessitating predictive biomarkers.

Purpose of the Study:

  • To develop and optimize a method for analyzing PD-L1 expression on circulating melanoma cells.
  • To identify potential biomarkers for predicting response to ICI therapy in melanoma patients.
  • To improve patient selection for immunotherapy.

Main Methods:

  • Immunomagnetic enrichment of circulating melanoma cells from patient blood samples.
  • Optimized analysis of PD-L1 expression on enriched circulating melanoma cells.
  • Method validation for reliable biomarker assessment.

Main Results:

  • Successfully optimized a method for analyzing PD-L1 expression on circulating melanoma cells.
  • Demonstrated the feasibility of using immunomagnetic enrichment for this analysis.
  • Established a basis for further investigation into PD-L1 as a predictive biomarker.

Conclusions:

  • The developed method allows for the analysis of PD-L1 expression on circulating melanoma cells.
  • This approach may aid in identifying patients likely to respond to PD-1/PD-L1 axis inhibitors.
  • Further validation is needed to establish clinical utility in melanoma treatment selection.